ABBOTT LABORATORIES (ABT) FY2026 YTD Q2 P&L / Income Statement

Revenue by Business Segment

2026-01-01 to 2026-06-30

Swipe to see the full flow
ABBOTT LABORATORIES (ABT) FY2026 YTD Q2 P&L / Income StatementIncome statement for 2026-01-01 through 2026-06-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUE RECONCILIATIONREVENUEGROSSOPERATINGPRE-TAXNETMedical DevicesDiagnostic ProductsNutritional ProductsEstablished Pharmaceutical ProductsNet salesRevenue before reconciliation (calculated)OtherGross profit (calculated)Cost of products sold, excluding amortization of intangible assetsOperating earningsOperating expenses (calculated)Selling, general, and administrativeResearch and developmentAmortization of intangible assetsEarnings before taxesOther income (expense), net (calculated)Net EarningsTaxes on earningsRevenue before reconciliation (calculated)Revenue beforereconciliation(calculated)$23.75 BGross profit (calculated)Gross profit(calculated)$13.54 BNet salesNet sales$23.76 BOperating earningsOperating earnings$3.04 BEarnings before taxesEarnings before taxes$2.97 BNet EarningsNet Earnings$2.01 BMedical DevicesMedical Devices$11.39 BOperating expenses (calculated)Operating expenses(calculated)$10.50 BTaxes on earningsTaxes on earnings$968.00 MOther income (expense), net (calculated)Other income,net (calculated)−$65.00 MSelling, general, and administrativeSelling, general, and administrative$7.77 BDiagnostic ProductsDiagnostic Products$5.27 BCost of products sold, excluding amortization of intangible assetsCost of products sold$10.22 BResearch and developmentResearch and development$1.66 BNutritional ProductsNutritional Products$4.16 BAmortization of intangible assetsAmortization of intangible assets$1.08 BEstablished Pharmaceutical ProductsEstablishedPharmaceuticalProducts$2.93 BOtherOther$7.00 M
Chart details

ABBOTT LABORATORIES (ABT) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net sales
23,757,000,000 US dollars
Cost of products sold, excluding amortization of intangible assets
10,215,000,000 US dollars
Gross profit (calculated)
13,542,000,000 US dollars
Operating expenses (calculated)
10,504,000,000 US dollars
Operating earnings
3,038,000,000 US dollars
Other income (expense), net (calculated)
negative 65,000,000 US dollars
Earnings before taxes
2,973,000,000 US dollars
Taxes on earnings
968,000,000 US dollars
Net Earnings
2,005,000,000 US dollars
Established Pharmaceutical Products
2,925,000,000 US dollars
Nutritional Products
4,161,000,000 US dollars
Diagnostic Products
5,272,000,000 US dollars
Medical Devices
11,392,000,000 US dollars
Amortization of intangible assets
1,080,000,000 US dollars
Research and development
1,659,000,000 US dollars
Selling, general, and administrative
7,765,000,000 US dollars
Revenue before reconciliation (calculated)
23,750,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
Other
7,000,000 US dollars. Reported reconciliation to consolidated revenue.
Established Pharmaceutical Products costs (calculated)
2,178,000,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.
Nutritional Products costs (calculated)
3,482,000,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.
Diagnostic Products costs (calculated)
4,438,000,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.
Medical Devices costs (calculated)
7,530,000,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.
Reconciling items (calculated)
3,091,000,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
  • Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
ABBOTT LABORATORIES (ABT) FY2026 YTD Q2 P&L / Income Statement Sankey chart, Business segment view
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

57.0%

Gross profit / revenue

Operating margin

12.8%

Operating profit / revenue

Cash conversion

189.7%

Operating cash / net income, same period

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!